Inovio reports fourth quarter and full year 2024 financial results and operational highlights

Significant progress toward submitting a biologics license application (bla) for ino-3107 as a potential treatment for recurrent respiratory papillomatosis (rrp) resolved previously announced manufacturing issue concerning the single-use array component of the cellectra device and completed drafting of all non-device bla modules on track to begin rolling submission of bla in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year announced durability data from retrospective study  showing that 50% of patients achieved a complete response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2; data to be included in bla submission announced promising interim results from ongoing proof-of-concept phase 1 trial showing dna-encoded monoclonal antibodies (dmab) targeting covid-19 were well tolerated and exhibited long-lasting in vivo production dmab technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases dna medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins plymouth meeting, pa. , march 18, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended december 31, 2024 and provided a business update and description of operational highlights during the year.
INO Ratings Summary
INO Quant Ranking